Combination Strategies A Common Thread In NASH R&D

Nov 21 2016

• By Joseph Haas

Listen to this article

Intercept continues to lead the non-alcoholic steatohepatitis race, but some analysts think Gilead is making up ground; data presented at AASLD shows those two, along with Allergan/Tobira and Bristol, are jockeying to produce combination regimens for the unmet medical need.

Liver

BOSTON – With hepatitis C on the decline, non-alcoholic steatohepatitis is becoming the focus of liver disease R&D. While Intercept Pharmaceuticals Inc. and Genfit SA have the early lead in drug development, recent deal-making by Allergan PLC and Bristol-Myers Squibb Co., as well as a reshuffled strategy at Gilead Sciences Inc., appear to have the competition in flux.

Intercept continues to lead the race to get the first drug approved for non-alcoholic steatohepatitis (NASH) with Ocaliva – but,...

More from Business

Test Roche Head Of Pharma Strategy Karsten Jung On Rebuilding The Portfolio
Jan 23 2026
• By Jessica Merrill
The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.
Quick Listen: Scrip’s Five Must-Know Things
Dec 09 2025
• By Reed Miller
In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.
Article Without An Author Listed
Nov 19 2025
Here is a short description.
Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]
Nov 12 2025
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance
Jul 15 2026
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone
Jun 18 2026
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Finance Watch: Biopharma IPOs On The Upswing, Including Ex-US Offerings
Jun 17 2026
ghghghghghjhjhjhj